

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

COMP/M.6113- DSM / SINOCHEM / JV

SECTION 1.2

Description of the concentration

On 08/04/2011, the European Commission received notification of a proposed concentration pursuant to Article 3(1)(b) of the Merger Regulation, according to which DSM and Sinochem will acquire joint control over DSM's existing Anti-Infectives business, which is active in the field of beta-lactam antibiotics in bulk and other anti-infective products and certain generic pharmaceutical products, mostly intended to be marketed and sold as active pharmaceutical ingredients or as finished dosage form.

DSM comprises a group of companies active worldwide in the nutritional and pharmaceutical sector, the performance materials sector and the industrial chemicals sector. DSM's products are used in a wide range of end markets and applications such as human and animal nutrition, cosmetics, pharmaceuticals, automotive and transport, coatings, housing and electrics & electronics.

Sinochem is a Chinese company active in five business segments, *i.e.*, agriculture, energy, chemical, real estate and finance business units.